Literature DB >> 12901797

Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma.

Yusuke Oji1, Hirofumi Yamamoto, Masaya Nomura, Yoko Nakano, Ai Ikeba, Shin-ichi Nakatsuka, Sakie Abeno, Eiji Kiyotoh, Tanyarat Jomgeow, Mitsugu Sekimoto, Riichiro Nezu, Yukinobu Yoshikawa, Yoshifumi Inoue, Naoki Hosen, Manabu Kawakami, Akihiro Tsuboi, Yoshihiro Oka, Hiroyasu Ogawa, Shigeo Souda, Katsuyuki Aozasa, Morito Monden, Haruo Sugiyama.   

Abstract

Expression of the Wilms' tumor gene WT1 was examined in 59 cases of colorectal adenocarcinoma to examine the involvement of WT1 in tumorigenesis. Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) showed that WT1 mRNA was expressed in the range from 7.2 x 10(-5) to 4.9 x 10(-1) levels (WT1 expression level in K562 leukemic cells was defined as 1.0) in all (100%) of the 28 cases of colorectal adenocarcinoma examined, and that the WT1 mRNA expression levels were higher in 20 (71%) of the 28 cases compared to those of normal-appearing mucosal tissues examined. Immunohistochemical analysis using an anti-WT1 antibody was performed on 46 cases of colorectal adenocarcinoma (15 of the 28 cases with WT1 mRNA expression and 31 newly collected cases), and the expression of WT1 protein was detected in 41 (89%) of the 46 cases. The direct sequencing analysis of the WT1 genomic DNA showed no mutations in any of the 10 exons of the WT1 gene in any of 5 different colorectal adenocarcinomas. These results may indicate an important role of the wild-type WT1 gene in tumorigenesis of colorectal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901797     DOI: 10.1111/j.1349-7006.2003.tb01507.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  29 in total

Review 1.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

2.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

3.  WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report.

Authors:  Ilda Patrícia Ribeiro; Francisco Caramelo; Francisco Marques; Ana Domingues; Margarida Mesquita; Leonor Barroso; Hugo Prazeres; Maria José Julião; Isabel Poiares Baptista; Artur Ferreira; Joana Barbosa Melo; Isabel Marques Carreira
Journal:  Cell Oncol (Dordr)       Date:  2016-08-04       Impact factor: 6.730

4.  Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.

Authors:  S Cedrés; M A Montero; E Zamora; A Martínez; P Martínez; L Fariñas; A Navarro; D Torrejon; A Gabaldon; S Ramon Y Cajal; E Felip
Journal:  Clin Transl Oncol       Date:  2013-12-10       Impact factor: 3.405

5.  Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

Authors:  Shuko Hakata; Jun Terashima; Yu Shimoyama; Kouji Okada; Shiho Fujioka; Erika Ito; Wataru Habano; Shogo Ozawa
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

6.  Dual use of a single Wilms' tumor 1 immunohistochemistry in evaluation of ovarian tumors: a preliminary study of 20 cases.

Authors:  Yi-Hsuan Hsiao; Sarwat Siddiqui; Yan-Gao Man
Journal:  J Cancer       Date:  2010-07-13       Impact factor: 4.207

7.  Wilms' tumor 1 gene (WT1) is overexpressed and provides an oncogenic function in pediatric nephroblastomas harboring the wild-type WT1.

Authors:  Surasak Sangkhathat; Samornmas Kanngurn; Welawee Chaiyapan; Podchanaporn Gridist; Wanwisa Maneechay
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

8.  WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi.

Authors:  Karli Rosner; Darius R Mehregan; Darius Moussai; Judith Abrams; Gerard Tromp; David A Mehregan
Journal:  J Cutan Pathol       Date:  2009-07-09       Impact factor: 1.587

9.  Wilms tumor gene single nucleotide polymorphism rs16754 predicts a favorable outcome in children with acute lymphoblastic leukemia.

Authors:  Anne-Sophie Junghanns; Susan Wittig; Caroline Woehlecke; Thomas Lehmann; Clemens Arndt; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-30       Impact factor: 4.553

10.  Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Tsunekazu Kita; Kazunari Maekawa; Kazuyuki Fujii; Kazuya Kudoh; Kenichi Furuya; Seiichi Tamai; Johji Inazawa; Osamu Matsubara
Journal:  Virchows Arch       Date:  2007-06-27       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.